{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:34Z","timestamp":1756902154113,"version":"3.44.0"},"reference-count":46,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Clonidine has been widely used in the pediatric population to treat neonatal abstinence syndrome (NAS), attention deficit hyperactivity disorder (ADHD), sedation, and Tourette\u2019s syndrome; however, there is no consensus on dosing. This research aims to recommend optimal dosing of clonidine in the pediatric population using physiologically based pharmacokinetic (PBPK) modeling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The pediatric PBPK model was developed from an adult model by scaling the clearance processes from adults to pediatrics using ontogeny equations. The adult and pediatric models were verified using clinical PK data, and the model performance was evaluated based on visual predictive checks and absolute fold error (AFE). The final pediatric PBPK model was used to simulate clonidine PK in the virtual pediatric population. The optimal dose was recommended based on a target concentration representing clonidine\u2019s \u03b1-2 central agonist activity (EC50 = 40.5 nM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The adult and pediatric models predicted well, with more than 90% of observed data captured within the 95% prediction interval of simulated data. The AFE values were within 2-fold for clonidine plasma concentrations from observed and predicted data. The pediatric simulations showed that 30 \u00b5g\/kg dose orally for neonates and 0.9 mg\/day orally for children (6\u201317 years) are optimal for achieving target concentrations for maximal \u03b1-2 adrenergic activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The pediatric PBPK model of clonidine scaled from the adult PBPK model provided optimal dosing recommendations for clonidine in different pediatric age groups. The pediatric PBPK model described in this study can be extended to other pediatric age groups and routes of administration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.6.636","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:36:57Z","timestamp":1733780217000},"page":"636-644","source":"Crossref","is-referenced-by-count":0,"title":["Optimal Dosing Recommendations of Clonidine in Pediatrics Using Physiologically Based Pharmacokinetic Modeling"],"prefix":"10.5863","volume":"29","author":[{"given":"Venkata","family":"Yellepeddi","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology (VKY, CMS), Department of Pediatrics, University of Utah, UT"},{"name":"Division of Molecular Pharmaceutics (VKY, MP), College of Pharmacy, University of Utah, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlo","family":"Bayless","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology (VKY, CMS), Department of Pediatrics, University of Utah, UT"},{"name":"Department of Psychiatry (SB), University of Buffalo, NY; Internal Medicine, UWA Medical School (CMS), The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Parrot","sequence":"additional","affiliation":[{"name":"Division of Molecular Pharmaceutics (VKY, MP), College of Pharmacy, University of Utah, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Sherwin","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology (VKY, CMS), Department of Pediatrics, University of Utah, UT"},{"name":"UWA Medical School, University of Western Australia; Boonshoft School of Medicine (CMS), Wright State University, OH"},{"name":"Differentia Biotech Ltd (CMS)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"3","key":"2024121714211172200_i2331-348X-29-6-636-b01","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/003693307902400311","article-title":"The therapeutic uses of clonidine","volume":"24","author":"Wood","year":"1979","journal-title":"Scott Med J"},{"key":"2024121714211172200_i2331-348X-29-6-636-b02","first-page":"171","article-title":"Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine","volume":"7","author":"Fitzgerald","year":"2013","journal-title":"Subst Abuse"},{"issue":"5","key":"2024121714211172200_i2331-348X-29-6-636-b03","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0033-0620(81)90020-7","article-title":"Clonidine hydrochloride: review of pharmacologic and clinical aspects","volume":"23","author":"Houston","year":"1981","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"2024121714211172200_i2331-348X-29-6-636-b04","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/cts.12994","article-title":"Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments","volume":"14","author":"Tang","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"3","key":"2024121714211172200_i2331-348X-29-6-636-b05","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.chc.2022.03.005","article-title":"Nonstimulant treatments for ADHD","volume":"31","author":"Newcorn","year":"2022","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"4","key":"2024121714211172200_i2331-348X-29-6-636-b06","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20040","article-title":"Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis","volume":"20","author":"Hollis","year":"2016","journal-title":"Health Technol Assess"},{"issue":"6","key":"2024121714211172200_i2331-348X-29-6-636-b07","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/15563650902980019","article-title":"Use of clonidine in the prevention and management of neonatal abstinence syndrome","volume":"47","author":"Leikin","year":"2009","journal-title":"Clin Toxicol (Phila)"},{"issue":"11","key":"2024121714211172200_i2331-348X-29-6-636-b08","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/pan.14740","article-title":"Postoperative recovery in preschool-aged children: a secondary analysis of a randomized controlled trial comparing premedication with midazolam, clonidine, and dexmedetomidine","volume":"33","author":"Bromfalk","year":"2023","journal-title":"Paediatr Anaesth"},{"issue":"12","key":"2024121714211172200_i2331-348X-29-6-636-b09","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/00004583-199912000-00017","article-title":"A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder","volume":"38","author":"Connor","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/000992280003900102","article-title":"A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder","volume":"39","author":"Connor","year":"2000","journal-title":"Clin Pediatr (Phila)"},{"issue":"6","key":"2024121714211172200_i2331-348X-29-6-636-b11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/bja\/83.6.945","article-title":"Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats","volume":"83","author":"Kubota","year":"1999","journal-title":"Br J Anaesth"},{"issue":"4","key":"2024121714211172200_i2331-348X-29-6-636-b12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","article-title":"Clonidine treatment of Gilles de la Tourette\u2019s syndrome","volume":"48","author":"Leckman","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"2024121714211172200_i2331-348X-29-6-636-b13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/02698811211032445","article-title":"Pharmacological treatment for Tourette syndrome in children and adults: what is the quality of the evidence? A systematic review","volume":"35","author":"Besag","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2024121714211172200_i2331-348X-29-6-636-b14","doi-asserted-by":"crossref","first-page":"632836","DOI":"10.3389\/fped.2021.632836","article-title":"A retrospective review following the addition of clonidine to a neonatal abstinence syndrome treatment algorithm","volume":"9","author":"Bader","year":"2021","journal-title":"Front Pediatr"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00609752","article-title":"Pharmacokinetics and side-effects of clonidine","volume":"13","author":"Keranen","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1365-2044.1999.00659.x","article-title":"Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role","volume":"54","author":"Khan","year":"1999","journal-title":"Anaesthesia"},{"issue":"6","key":"2024121714211172200_i2331-348X-29-6-636-b17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ecp.09.40","article-title":"Challenges in conducting clinical trials in children: approaches for improving performance","volume":"2","author":"Kern","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-018-0677-y","article-title":"State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development","volume":"58","author":"Yellepeddi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2024121714211172200_i2331-348X-29-6-636-b20","unstructured":"Open Systems Pharmacology Suite Manual. Accessed July 31, 2023. https:\/\/www.open-systems-pharmacology.org\/"},{"key":"2024121714211172200_i2331-348X-29-6-636-b21","unstructured":"Clonidine. Accessed July\n            \n          \n          31, 2023. https:\/\/go.drugbank.com\/drugs\/DB00575"},{"issue":"4","key":"2024121714211172200_i2331-348X-29-6-636-b22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/dmd.112.050161","article-title":"A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women","volume":"41","author":"Ke","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2024121714211172200_i2331-348X-29-6-636-b23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2125.1978.tb04589.x","article-title":"Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients","volume":"6","author":"Frisk-Holmberg","year":"1978","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2024121714211172200_i2331-348X-29-6-636-b24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2125.1981.tb01284.x","article-title":"Clonidine kinetics in man\u2013evidence for dose dependency and changed pharmacokinetics during chronic therapy","volume":"12","author":"Frisk-Holmberg","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","article-title":"A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam","volume":"15","author":"Maharaj","year":"2013","journal-title":"AAPS J"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01061368","article-title":"Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects","volume":"23","author":"Anavekar","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00613922","article-title":"New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man","volume":"24","author":"Arndts","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2024121714211172200_i2331-348X-29-6-636-b28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00561067","article-title":"Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension","volume":"12","author":"Wing","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"2024121714211172200_i2331-348X-29-6-636-b29","unstructured":"PK Sim\n          \n          \n            Ontogeny Database Version 7.3\n          . Accessed August 14, 2023. https:\/\/github.com\/Open-Systems-Pharmacology\/OSPSuite.Documentation\/blob\/master\/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf"},{"issue":"5","key":"2024121714211172200_i2331-348X-29-6-636-b30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pan.13856","article-title":"Pharmacokinetics of an intravenous bolus dose of clonidine in children undergoing surgery","volume":"30","author":"Nielsen","year":"2020","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"2024121714211172200_i2331-348X-29-6-636-b31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1460-9592.2010.03397.x","article-title":"Oral bioavailability of clonidine in children","volume":"21","author":"Larsson","year":"2011","journal-title":"Paediatr Anaesth"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S1092852920001984","article-title":"Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents","volume":"27","author":"Cutler","year":"2022","journal-title":"CNS Spectr"},{"key":"2024121714211172200_i2331-348X-29-6-636-b33","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4306\/pi.2018.15.1.90","article-title":"Treatment of children and adolescents with attention deficit hyperactivity disorder and\/or Tourette\u2019s disorder with clonidine extended release","volume":"15","author":"Joo","year":"2018","journal-title":"Psychiatry Investig"},{"issue":"5","key":"2024121714211172200_i2331-348X-29-6-636-b35","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1542\/peds.2008-0978","article-title":"Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial","volume":"123","author":"Agthe","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jpc.15265","article-title":"Does the addition of clonidine to opioid therapy improve outcomes in infants with neonatal abstinence syndrome?","volume":"57","author":"D\u2019Abaco","year":"2021","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/neurolint15020043","article-title":"The role of alpha-2 agonists for attention deficit hyperactivity disorder in children: a review","volume":"15","author":"Neuchat","year":"2023","journal-title":"Neurol Int"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-017-0486-0","article-title":"Current approaches and new developments in the pharmacological management of Tourette syndrome","volume":"32","author":"Quezada","year":"2018","journal-title":"CNS Drugs"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/ALN.0b013e3181943226","article-title":"Alpha-1-adrenergic receptor agonist activity of clinical alpha-adrenergic receptor agonists interferes with alpha-2-mediated analgesia","volume":"110","author":"Gil","year":"2009","journal-title":"Anesthesiology"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1213\/00000539-199408000-00009","article-title":"The effect of clonidine on the activity of neurons in the rat dorsal raphe nucleus in vitro","volume":"79","author":"Alojado","year":"1994","journal-title":"Anesth Analg"},{"key":"2024121714211172200_i2331-348X-29-6-636-b41","unstructured":"Amneal Pharmaceuticals NY LLC. Clonidine hydrochloride - clonidine tablet, extended release. 2020 [rev. February 2020; cited April 2023]. In: DailyMed [Internet]. Bethesda, MD: National Library of Medicine (US); 2005. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=accb2879-7c0e-40d9-bc78-af78fc619609"},{"key":"2024121714211172200_i2331-348X-29-6-636-b42","unstructured":"Lindsay\n              B\n            \n          . Watch, listen, and discover with Canada\u2019s public broadcaster. CBCnews, CBC\/Radio Canada, March 16, 2023. https:\/\/www.cbc.ca\/"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pharmrev.120.000071","article-title":"Ontogeny of hepatic transporters and drug-metabolizing enzymes in humans and in nonclinical species","volume":"73","author":"van Groen","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"12","key":"2024121714211172200_i2331-348X-29-6-636-b44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1542\/pir.19.12.423","article-title":"Clinical pharmacology and therapeutic drug monitoring in neonates and children","volume":"19","author":"Loebstein","year":"1998","journal-title":"Pediatr Rev"},{"issue":"1","key":"2024121714211172200_i2331-348X-29-6-636-b45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/039463201402700102","article-title":"Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology","volume":"27","author":"Fanni","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"2024121714211172200_i2331-348X-29-6-636-b46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jcph.1725","article-title":"Does \u201cbirth\u201d as an event impact maturation trajectory of renal clearance via glomerular filtration? Reexamining data in preterm and full-term neonates by avoiding the creatinine bias","volume":"61","author":"Salem","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/6\/636\/3465995\/i2331-348x-29-6-636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/6\/636\/3465995\/i2331-348x-29-6-636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:42:22Z","timestamp":1738780942000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/6\/article-p636.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.6.636","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}